Form 4: Seres Therapeutics Executive von Moltke Granted Stock Options

Lisa von Moltke, Executive Vice President and Chief Medical Officer of Seres Therapeutics, was granted stock options to purchase 650,000 shares of common stock.

Summary

• Lisa von Moltke, an executive at Seres Therapeutics, received stock options on February 7, 2025.
• The options grant her the right to purchase 650,000 shares of Seres Therapeutics common stock at an exercise price of $0.782 per share.
• The options vest as to 25% of the shares on February 7, 2026, with the remaining shares vesting in 12 equal quarterly installments thereafter.
• The options expire on February 6, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine grant of stock options, which is neither particularly positive nor negative on its own. It's a standard practice for executive compensation.

Positives

• The granting of stock options to a key executive aligns her interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the executive.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. Grants of this size are not unusual for executives at publicly traded biotech companies.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in the biotechnology industry.
• Companies like Gilead Sciences, Amgen, and Biogen routinely grant stock options to their executives as part of their overall compensation strategy.
• The size of the grant (650,000 shares) is within the typical range for an executive at a company with a similar market capitalization to Seres Therapeutics.

Stakeholder Impact

• Shareholders may view the grant positively as it incentivizes the executive to increase shareholder value.
• Employees may see it as a positive sign of the company's commitment to its leadership.

Key Dates